QQQ   431.85 (+0.18%)
AAPL   169.39 (-1.91%)
MSFT   416.10 (+0.59%)
META   502.92 (+0.54%)
GOOGL   154.87 (+0.01%)
AMZN   183.74 (+0.07%)
TSLA   157.22 (-2.64%)
NVDA   870.95 (+1.27%)
AMD   163.20 (+1.80%)
NIO   3.82 (-1.80%)
BABA   69.84 (-1.10%)
T   16.08 (-0.99%)
F   12.17 (-0.49%)
MU   121.16 (-0.17%)
GE   155.69 (+1.29%)
CGC   6.88 (-1.43%)
DIS   114.19 (+1.10%)
AMC   2.71 (+9.72%)
PFE   25.84 (-0.27%)
PYPL   64.04 (+0.83%)
XOM   118.87 (-0.68%)
QQQ   431.85 (+0.18%)
AAPL   169.39 (-1.91%)
MSFT   416.10 (+0.59%)
META   502.92 (+0.54%)
GOOGL   154.87 (+0.01%)
AMZN   183.74 (+0.07%)
TSLA   157.22 (-2.64%)
NVDA   870.95 (+1.27%)
AMD   163.20 (+1.80%)
NIO   3.82 (-1.80%)
BABA   69.84 (-1.10%)
T   16.08 (-0.99%)
F   12.17 (-0.49%)
MU   121.16 (-0.17%)
GE   155.69 (+1.29%)
CGC   6.88 (-1.43%)
DIS   114.19 (+1.10%)
AMC   2.71 (+9.72%)
PFE   25.84 (-0.27%)
PYPL   64.04 (+0.83%)
XOM   118.87 (-0.68%)
QQQ   431.85 (+0.18%)
AAPL   169.39 (-1.91%)
MSFT   416.10 (+0.59%)
META   502.92 (+0.54%)
GOOGL   154.87 (+0.01%)
AMZN   183.74 (+0.07%)
TSLA   157.22 (-2.64%)
NVDA   870.95 (+1.27%)
AMD   163.20 (+1.80%)
NIO   3.82 (-1.80%)
BABA   69.84 (-1.10%)
T   16.08 (-0.99%)
F   12.17 (-0.49%)
MU   121.16 (-0.17%)
GE   155.69 (+1.29%)
CGC   6.88 (-1.43%)
DIS   114.19 (+1.10%)
AMC   2.71 (+9.72%)
PFE   25.84 (-0.27%)
PYPL   64.04 (+0.83%)
XOM   118.87 (-0.68%)
QQQ   431.85 (+0.18%)
AAPL   169.39 (-1.91%)
MSFT   416.10 (+0.59%)
META   502.92 (+0.54%)
GOOGL   154.87 (+0.01%)
AMZN   183.74 (+0.07%)
TSLA   157.22 (-2.64%)
NVDA   870.95 (+1.27%)
AMD   163.20 (+1.80%)
NIO   3.82 (-1.80%)
BABA   69.84 (-1.10%)
T   16.08 (-0.99%)
F   12.17 (-0.49%)
MU   121.16 (-0.17%)
GE   155.69 (+1.29%)
CGC   6.88 (-1.43%)
DIS   114.19 (+1.10%)
AMC   2.71 (+9.72%)
PFE   25.84 (-0.27%)
PYPL   64.04 (+0.83%)
XOM   118.87 (-0.68%)
NASDAQ:TSVT

2seventy bio (TSVT) Stock Price, News & Analysis

$4.89
-0.10 (-2.00%)
(As of 12:36 PM ET)
Today's Range
$4.70
$4.99
50-Day Range
$3.96
$6.00
52-Week Range
$1.53
$12.69
Volume
459,990 shs
Average Volume
1.42 million shs
Market Capitalization
$250.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.17

2seventy bio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
169.3% Upside
$13.17 Price Target
Short Interest
Bearish
14.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of 2seventy bio in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$3.14 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.39) to $0.07 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.53 out of 5 stars

Medical Sector

275th out of 930 stocks

Pharmaceutical Preparations Industry

121st out of 428 stocks

TSVT stock logo

About 2seventy bio Stock (NASDAQ:TSVT)

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

TSVT Stock Price History

TSVT Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
2seventy bio Inc Ordinary Shares
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Bristol Myers Wins FDA Nod for Abecma
See More Headlines
Receive TSVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
4/16/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TSVT
Fax
N/A
Employees
274
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.17
High Stock Price Target
$26.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+169.3%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
$-217,570,000.00
Net Margins
-216.73%
Pretax Margin
-216.73%

Debt

Sales & Book Value

Annual Sales
$100.39 million
Book Value
$5.04 per share

Miscellaneous

Free Float
49,977,000
Market Cap
$250.91 million
Optionable
Optionable
Beta
1.84
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives


TSVT Stock Analysis - Frequently Asked Questions

Should I buy or sell 2seventy bio stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares.
View TSVT analyst ratings
or view top-rated stocks.

What is 2seventy bio's stock price target for 2024?

8 analysts have issued 12 month price objectives for 2seventy bio's shares. Their TSVT share price targets range from $5.00 to $26.00. On average, they expect the company's share price to reach $13.17 in the next year. This suggests a possible upside of 169.3% from the stock's current price.
View analysts price targets for TSVT
or view top-rated stocks among Wall Street analysts.

How have TSVT shares performed in 2024?

2seventy bio's stock was trading at $4.27 on January 1st, 2024. Since then, TSVT shares have increased by 14.5% and is now trading at $4.89.
View the best growth stocks for 2024 here
.

Are investors shorting 2seventy bio?

2seventy bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 6,810,000 shares, an increase of 29.7% from the March 15th total of 5,250,000 shares. Based on an average daily volume of 1,450,000 shares, the days-to-cover ratio is currently 4.7 days. Approximately 14.3% of the company's shares are short sold.
View 2seventy bio's Short Interest
.

When is 2seventy bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our TSVT earnings forecast
.

How were 2seventy bio's earnings last quarter?

2seventy bio, Inc. (NASDAQ:TSVT) released its quarterly earnings data on Tuesday, March, 5th. The company reported ($1.11) EPS for the quarter, topping analysts' consensus estimates of ($1.22) by $0.11. The business earned $10.68 million during the quarter, compared to analysts' expectations of $13.91 million. 2seventy bio had a negative net margin of 216.73% and a negative trailing twelve-month return on equity of 59.19%. During the same quarter last year, the firm posted ($0.60) earnings per share.

What ETFs hold 2seventy bio's stock?
Who are 2seventy bio's major shareholders?

2seventy bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wedmont Private Capital (0.17%). Insiders that own company stock include Casdin Capital, Llc, Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III.
View institutional ownership trends
.

How do I buy shares of 2seventy bio?

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TSVT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners